Neon Bloom, Inc. (OTC: NBCO) April 8th, 2021 Columbia, Maryland: Bazelet Health Systems, Inc. (“BHS”) introduces Board Certified Dr. Francisco Ward as their new chief medical officer (CMO). Dr. Ward is a DEA licensed physician, graduate of Johns Hopkins School of Medicine and founder of Seton Pain & Rehabilitation Center. Dr. Ward has worked with the Maryland Board of Physicians and the DEA successfully for many years and combines trusted traditional medical background with substantial eloquence on the human endocannabinoid system, “ECS” and the cannabinoid landscape.
Dr. Ward, working from the Company’s Columbia, Maryland medical offices will be responsible for the execution of Bazelet’s healthcare programs, clinical research, and patient experience standards. As CMO, Dr. Ward will manage relationships with US healthcare entities, insurers, regulators and the global medical and research community.
Selected as a greater Baltimore region “Top Doc”, Dr. Ward has served as Maryland State Medical Society chair of the medical cannabis Task Force. His expert understanding of the endocannabinoid system, the musculoskeletal system and its influences on other body systems align with Bazelet Health’s priorities.
David Grand, Director of Research for Bazelet states “I am excited and confident in Dr. Ward. His substantial knowledge and experience as a practitioner and as a healthcare board member, is trusted to run Bazelet Health’s medical practice. Dr. Ward will lead BHS on its deliberate strategy of effective medical treatment and patient experience through exceptional phytogenetics, clinical research and reimagined, patient centered healthcare.”
“Dr. Ward brings over 25 years medical knowledge, healthcare leadership, and patient care experience. Those skillsets and being well learned in the human ECS and cannabinoids make Dr. Ward well suited to lead a modern-day healthcare company like Bazelet Health. We are pleased to welcome him to our organization.” Said Bazelet co-founder and Medical Director Steven Salsburg, MD.
About Neon Bloom, Inc.
Neon Bloom, Inc. wholly owns Bazelet Health Systems, Inc. (BHS). BHS is the global forefront of the legal cannabis industry and represents a deliberate strategy to create a centralized focus on effective medical treatment and healthcare through exceptional genetics, research, and education.
This Press Release is for informational purposes, contains forward-looking statements based on current expectations, forecasts, and assumptions with information available to us as of the date hereof and involve risks and uncertainties. This Press Release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Actual results may differ materially from those stated or implied in such forward-looking statements. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forwardlooking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “would” or similar words. We assume no obligation to update the information included in this Press Release, whether a result of new information, future events or otherwise.